ketamine has been researched along with Benign Neoplasms in 122 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to examine the rapid antidepressant effects of single dose ketamine on suicidal ideation and overall depression level in patients with newly-diagnosed cancer." | 9.24 | Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. ( Fan, W; Li, G; Liu, Y; Sun, Y; Yang, H; Zhang, J; Zheng, Y, 2017) |
| " Ketamine is a commonly used anaesthetic agent, and in subanaesthetic doses is also given as an adjuvant to opioids for the treatment of cancer pain, particularly when opioids alone prove to be ineffective." | 8.88 | Ketamine as an adjuvant to opioids for cancer pain. ( Bell, RF; Eccleston, C; Kalso, EA, 2012) |
| "Ketamine is a commonly used anaesthetic agent, and in subanaesthetic doses is also given as an adjuvant to opioids for the treatment of cancer pain, particularly when opioids alone prove to be ineffective." | 8.82 | Ketamine as an adjuvant to opioids for cancer pain. ( Bell, R; Eccleston, C; Kalso, E, 2003) |
| "Ketamine is an effective analgesic agent for treating a variety of neuropathic and cancer pain syndromes." | 8.82 | Parenteral ketamine as an analgesic adjuvant for severe pain: development and retrospective audit of a protocol for a palliative care unit. ( Fitzgibbon, EJ; Viola, R, 2005) |
| "Ketamine is increasingly being used as an adjuvant to opioids in the treatment of refractory cancer pain." | 8.82 | Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. ( Bell, RF; Eccleston, C; Kalso, E, 2003) |
| "To review the clinical literature evaluating the utilization of intravenous ketamine for the management of cancer-related pain, to summarize the data that suggest ketamine is an appropriate adjuvant method of providing analgesia and to report a case of successful pain management using ketamine in a patient with recurrent testicular cancer at our institution." | 8.81 | Adjuvant ketamine analgesia for the management of cancer pain. ( Baroletti, SA; McQueen, AL, 2002) |
| "The objective of our study was to determine safety and pharmacology (pharmacokinetics and preliminary efficacy) of intranasal (IN) ketamine for uncontrolled cancer-related pain." | 8.12 | A dose-escalation clinical trial of intranasal ketamine for uncontrolled cancer-related pain. ( Beumer, JH; Curseen, K; Egan, K; Gillespie, TW; Harvey, RD; Lane, O; Shteamer, JW; Singh, V; Sniecinski, R; Spektor, B; Switchenko, J; Tsvetkova, M; Zarrabi, AJ, 2022) |
| "Ketamine has been used as an adjuvant to opioid therapy for the management of refractory cancer pain but the current evidence is insufficient to draw any conclusions regarding its efficacy." | 7.96 | The use of ketamine in the management of refractory cancer pain in a palliative care unit. ( Chan, PC; Cheung, KWA; Lo, SH, 2020) |
| "Questions have been raised about the potential neurotoxicity of the neuraxial use of ketamine although ketamine and its active enantiomer S(+)-ketamine have been used intrathecally and epidurally (caudally) for the management of perioperative pain and in a variety of chronic pain syndromes." | 7.73 | Neuropathological findings after continuous intrathecal administration of S(+)-ketamine for the management of neuropathic cancer pain. ( Kruis, MR; Troost, D; van der Vegt, MH; Vranken, JH; Wegener, JT, 2005) |
| "We evaluated the safety and efficacy of midazolam-ketamine association to control pain induced by diagnostic procedures in paediatric oncology patients." | 7.70 | Use of intravenous ketamine-midazolam association for pain procedures in children with cancer. A prospective study. ( Granry, JC; Le Moine, P; Monrigal, JP; Pellier, I; Rialland, X; Rod, B, 1999) |
| "To assess the benefit of ketamine addition to a morphine-clonidine-lidocaine mixture administered continuously by the intrathecal route for the treatment of cancer pain." | 7.69 | [Cancer pain: beneficial effect of ketamine addition to spinal administration of morphine-clonidine-lidocaine mixture]. ( Lemos, D; Muller, A, 1996) |
| "The effect of ketamine infusion to control the intractable pain which had not responded to ordinary procedures in 12 patients with advanced cancer were evaluated." | 7.68 | [Ketamine infusion for control of pain in patients with advanced cancer]. ( Kanamaru, T; Katsumata, N; Mizuno, K; Ogawa, S; Saeki, S; Suzuki, H, 1990) |
| "Ketamine is a lipophilic, general anesthetic." | 6.48 | Ketamine for pain: an update of uses in palliative care. ( Prommer, EE, 2012) |
| " Nursing considerations include close monitoring of vital signs during the initial dosage and follow-up observations of the effectiveness of the medications." | 6.44 | The use of ketamine as adjuvant therapy to control severe pain. ( Campbell-Fleming, JM; Williams, A, 2008) |
| "Ketamine is a dissociative anaesthetic; its mechanism of action is primarily an antagonism of the N-methyl-D-aspartate (NMDA) receptor." | 6.43 | The role of ketamine in pain management. ( Schug, SA; Visser, E, 2006) |
| "Ketamine has been shown to have potent analgesic properties at low dosages." | 6.39 | Ketamine in cancer pain: an update. ( Mercadante, S, 1996) |
| "Ketamine has shown promise as an effective adjuvant despite conflicting reports." | 5.62 | Subanesthetic ketamine in the ambulatory setting for refractory cancer pain: a 6-year retrospective at a cancer center. ( Benkli, B; Chung, M; Huh, B; Qing, Y; Roldan, C; Wang, J, 2021) |
| "Patients with advanced cancer often suffer from both severe pain and severe symptoms of depression." | 5.48 | Case Report: Ketamine for Pain and Depression in Advanced Cancer. ( Atayee, RS; Bruner, HC; Sexton, J, 2018) |
| " This adverse effect has not been reported previously at this dosing range." | 5.46 | A Case Report: Subanesthetic Ketamine Infusion for Treatment of Cancer-Related Pain Produces Urinary Urge Incontinence. ( Hunsberger, J; Lee, W; Vickers, BA, 2017) |
| "Pain was also improved, although for a shorter duration." | 5.38 | Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. ( Glue, P; Perez, D; Zanicotti, CG, 2012) |
| "This study was designed to examine the rapid antidepressant effects of single dose ketamine on suicidal ideation and overall depression level in patients with newly-diagnosed cancer." | 5.24 | Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. ( Fan, W; Li, G; Liu, Y; Sun, Y; Yang, H; Zhang, J; Zheng, Y, 2017) |
| "To determine the differences by comparing fentanyl and ketamine used in cancer-diagnosed children undergoing painful procedures." | 5.20 | The clinical effect of fentanyl in comparison with ketamine in analgesic effect for oncology procedures in children: a randomized, double-blinded, crossover trial. ( Monsereenusorn, C; Rujkijyanont, P; Traivaree, C, 2015) |
| "Midazolam/ketamine sedation has been used successfully in children undergoing painful invasive procedures." | 5.11 | Inter- and intraindividual variability in ketamine dosage in repetitive invasive procedures in children with malignancies. ( Aliani, S; Gottschling, S; Graf, N; Meyer, S, 2004) |
| " Ketamine is a commonly used anaesthetic agent, and in subanaesthetic doses is also given as an adjuvant to opioids for the treatment of cancer pain, particularly when opioids alone prove to be ineffective." | 4.88 | Ketamine as an adjuvant to opioids for cancer pain. ( Bell, RF; Eccleston, C; Kalso, EA, 2012) |
| "Ketamine is increasingly being used as an adjuvant to opioids in the treatment of refractory cancer pain." | 4.82 | Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. ( Bell, RF; Eccleston, C; Kalso, E, 2003) |
| "Ketamine is a commonly used anaesthetic agent, and in subanaesthetic doses is also given as an adjuvant to opioids for the treatment of cancer pain, particularly when opioids alone prove to be ineffective." | 4.82 | Ketamine as an adjuvant to opioids for cancer pain. ( Bell, R; Eccleston, C; Kalso, E, 2003) |
| "Ketamine is an effective analgesic agent for treating a variety of neuropathic and cancer pain syndromes." | 4.82 | Parenteral ketamine as an analgesic adjuvant for severe pain: development and retrospective audit of a protocol for a palliative care unit. ( Fitzgibbon, EJ; Viola, R, 2005) |
| " Evidence presented in this review shows encouraging results following the administration of methadone, fentanyl or ketamine to patients with difficult pain problems." | 4.82 | Morphine is not the only analgesic in palliative care: literature review. ( Wootton, M, 2004) |
| "To review the clinical literature evaluating the utilization of intravenous ketamine for the management of cancer-related pain, to summarize the data that suggest ketamine is an appropriate adjuvant method of providing analgesia and to report a case of successful pain management using ketamine in a patient with recurrent testicular cancer at our institution." | 4.81 | Adjuvant ketamine analgesia for the management of cancer pain. ( Baroletti, SA; McQueen, AL, 2002) |
| " The acute pain group did not show an opioid reduction associated with the ketamine infusions." | 4.12 | Low-dose ketamine infusions reduce opioid use in pediatric and young adult oncology patients. ( Anghelescu, DL; Li, Y; Morgan, KJ; Patni, T; Ryan, S; Wu, D, 2022) |
| "This prospective, multicentre, observational trial collected data regarding demographics, pain characteristics, pain score assessment within the first 48 hours of ketamine administration, tolerance and satisfaction from 38 patients aged 2-24 years prescribed with ketamine as an adjuvant antalgic for refractory cancer pain in 10 French paediatric oncology centres." | 4.12 | Low-dose ketamine adjuvant treatment for refractory pain in children, adolescents and young adults with cancer: a pilot study. ( Bertrand, A; Cojean, N; Courade, M; Dugue, S; Guerrini-Rousseau, L; Lervat, C; Levy, D; Marec-Berard, P; Pagnier, A; Piguet, C; Ribrault, A; Schmitt, C; Thouvenin, S, 2022) |
| "The objective of our study was to determine safety and pharmacology (pharmacokinetics and preliminary efficacy) of intranasal (IN) ketamine for uncontrolled cancer-related pain." | 4.12 | A dose-escalation clinical trial of intranasal ketamine for uncontrolled cancer-related pain. ( Beumer, JH; Curseen, K; Egan, K; Gillespie, TW; Harvey, RD; Lane, O; Shteamer, JW; Singh, V; Sniecinski, R; Spektor, B; Switchenko, J; Tsvetkova, M; Zarrabi, AJ, 2022) |
| "Ketamine has been used as an adjuvant to opioid therapy for the management of refractory cancer pain but the current evidence is insufficient to draw any conclusions regarding its efficacy." | 3.96 | The use of ketamine in the management of refractory cancer pain in a palliative care unit. ( Chan, PC; Cheung, KWA; Lo, SH, 2020) |
| "Questions have been raised about the potential neurotoxicity of the neuraxial use of ketamine although ketamine and its active enantiomer S(+)-ketamine have been used intrathecally and epidurally (caudally) for the management of perioperative pain and in a variety of chronic pain syndromes." | 3.73 | Neuropathological findings after continuous intrathecal administration of S(+)-ketamine for the management of neuropathic cancer pain. ( Kruis, MR; Troost, D; van der Vegt, MH; Vranken, JH; Wegener, JT, 2005) |
| " These address opioids for the management of breakthrough (episodic) pain in cancer patients, perioperative ketamine for acute postoperative pain, and superficial heat or cold for low back pain." | 3.73 | Evidence-based pain management and palliative care in Issue One for 2006 of The Cochrane Library. ( Wiffen, PJ, 2006) |
| "We evaluated the safety and efficacy of midazolam-ketamine association to control pain induced by diagnostic procedures in paediatric oncology patients." | 3.70 | Use of intravenous ketamine-midazolam association for pain procedures in children with cancer. A prospective study. ( Granry, JC; Le Moine, P; Monrigal, JP; Pellier, I; Rialland, X; Rod, B, 1999) |
| "To assess the benefit of ketamine addition to a morphine-clonidine-lidocaine mixture administered continuously by the intrathecal route for the treatment of cancer pain." | 3.69 | [Cancer pain: beneficial effect of ketamine addition to spinal administration of morphine-clonidine-lidocaine mixture]. ( Lemos, D; Muller, A, 1996) |
| "The effect of ketamine infusion to control the intractable pain which had not responded to ordinary procedures in 12 patients with advanced cancer were evaluated." | 3.68 | [Ketamine infusion for control of pain in patients with advanced cancer]. ( Kanamaru, T; Katsumata, N; Mizuno, K; Ogawa, S; Saeki, S; Suzuki, H, 1990) |
| " The efficacy and safety of the sedations including sedation time intervals, nausea score, vomiting episodes, pain score, adverse effects, and parent's satisfaction were evaluated." | 3.11 | The efficacy and safety of midazolam with fentanyl versus midazolam with ketamine for bedside invasive procedural sedation in pediatric oncology patients: A randomized, double-blinded, crossover trial. ( Lertvivatpong, N; Malaithong, W; Monsereenusorn, C; Photia, A; Rujkijyanont, P; Traivaree, C, 2022) |
| "Ketamine oral rinse has shown promising results in a few studies in adults." | 2.94 | Ketamine mouthwash versus placebo in the treatment of severe oral mucositis pain in children with cancer: A randomized double-blind placebo-controlled trial. ( Bakhshi, S; Gupta, AK; Meena, JP; Pandey, RM; Prakash, S; Seth, R; Velpandian, T, 2020) |
| " There was almost twice the incidence of adverse events worse than baseline in the ketamine group after day 1 (incidence rate ratio, 1." | 2.77 | Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. ( Agar, M; Currow, DC; Eckermann, S; Fazekas, B; Hardy, J; Plummer, J; Quinn, S; Rowett, D; Spruyt, O, 2012) |
| "ketamine bolus, were treated with 0." | 2.76 | A strategy for conversion from subcutaneous to oral ketamine in cancer pain patients: effect of a 1:1 ratio. ( Benítez-Rosario, MA; Feria, M; González-Guillermo, T; Salinas-Martín, A, 2011) |
| "Ketamine induces a short-term effect on postoperative pain when administered intravenously immediately before or during acute pain." | 2.76 | Repeated and escalating preoperative subanesthetic doses of ketamine for postoperative pain control in patients undergoing tumor resection: a randomized, placebo-controlled, double-blind trial. ( Amar, E; Bickels, J; Chazan, S; Dadia, S; Ekstein, MP; Kollender, Y; Rakhman, E; Shmain, D; Weinbroum, AA; White, I, 2011) |
| "This multi-centre study of adjuvant "burst" ketamine in palliative care in-patients documents its effectiveness, duration of pain relief, and adverse effects (AE) profile." | 2.75 | The effectiveness and adverse effects profile of "burst" ketamine in refractory cancer pain: The VCOG PM 1-00 study. ( Ashby, M; Brumley, D; Good, P; Howell, D; Jackson, K; Petersen, J; Pisasale, M; Wein, S; Woodruff, R, 2010) |
| "Ketamine is a dissociative anesthetic agent with excellent analgesic properties and a favorable safety profile." | 2.72 | A review of the clinical applications of ketamine in pediatric oncology. ( Gupta, AK; Meena, JP; Prakash, S; Seth, R, 2021) |
| "The morphine regimen was adjusted individually to a maximal oral dose of 80-90 mg/day to keep the visual analog scale score less than 4." | 2.69 | Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. ( Lauretti, GR; Lima, IC; Pereira, NL; Prado, WA; Reis, MP, 1999) |
| "48 terminal cancer patients suffering from chronic pain." | 2.69 | Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. ( Gomes, JM; Lauretti, GR; Pereira, NL; Reis, MP, 1999) |
| "Quality pain management for cancer survivors is complicated by the fact that cancer-related pain can be due to the tumor, surgery, radiation, and/or chemotherapy." | 2.50 | Understanding the cancer pain experience. ( Schreiber, JA, 2014) |
| "Ketamine is a medication with evidence of efficacy in the treatment of chronic pain." | 2.49 | Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. ( Bredlau, AL; Dworkin, RH; Korones, DN; Thakur, R, 2013) |
| "Ketamine is a lipophilic, general anesthetic." | 2.48 | Ketamine for pain: an update of uses in palliative care. ( Prommer, EE, 2012) |
| " Nursing considerations include close monitoring of vital signs during the initial dosage and follow-up observations of the effectiveness of the medications." | 2.44 | The use of ketamine as adjuvant therapy to control severe pain. ( Campbell-Fleming, JM; Williams, A, 2008) |
| "Ketamine is a dissociative anaesthetic; its mechanism of action is primarily an antagonism of the N-methyl-D-aspartate (NMDA) receptor." | 2.43 | The role of ketamine in pain management. ( Schug, SA; Visser, E, 2006) |
| "Pain is the primary problem targeted for control using the World Health Organization's (WHO) analgesic ladder." | 2.41 | Advances in cancer pain management. ( Hamann, SR; McDonnell, FJ; Sloan, JW, 2000) |
| "Tramadol is a centrally acting analgesic drug; it has an agonist effect on mu 1 receptors of opioids and acts also by inhibiting the re-uptake of noradrenaline and serotonine which activates descending monoaminergic inhibitory pathways." | 2.40 | [Treatment of pain in oncology]. ( De Conno, F; Polastri, D, 1997) |
| "Ketamine has been shown to have potent analgesic properties at low dosages." | 2.39 | Ketamine in cancer pain: an update. ( Mercadante, S, 1996) |
| "An orthotropic breast cancer model was established by injecting EO771 breast cancer cells into the mammary fat pad of mice intraperitoneally administered ketamine (30 mg/kg, daily) for 68 days." | 1.91 | Ketamine Promoted Breast Cancer Invasion and Metastasis Through Up-regulating Wnt, BMP, and EGFR Signaling. ( Chen, KB; Chen, L; Chen, LK; Chen, SS; Huang, ZX; Shih, CH, 2023) |
| "Ketamine is a fast-acting N-methyl-D-aspartate (NMDA) receptor antagonist that has been emerging as an effective medication for pain alleviation." | 1.62 | Low-dose ketamine as an adjuvant for pain control in a cancer patient: a case report. ( Fattakhov, E; Galea, J; Kaur, G; Patel, S; Singh, AB; Tatachar, V, 2021) |
| "Ketamine has shown promise as an effective adjuvant despite conflicting reports." | 1.62 | Subanesthetic ketamine in the ambulatory setting for refractory cancer pain: a 6-year retrospective at a cancer center. ( Benkli, B; Chung, M; Huh, B; Qing, Y; Roldan, C; Wang, J, 2021) |
| "Pharmacological management of neuropathic pain should be based on a stepwise intervention strategy, as combinations of medications are the most effective approach." | 1.51 | Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm. ( Anghelescu, DL; Tesney, JM, 2019) |
| "Patients with advanced cancer often suffer from both severe pain and severe symptoms of depression." | 1.48 | Case Report: Ketamine for Pain and Depression in Advanced Cancer. ( Atayee, RS; Bruner, HC; Sexton, J, 2018) |
| " This adverse effect has not been reported previously at this dosing range." | 1.46 | A Case Report: Subanesthetic Ketamine Infusion for Treatment of Cancer-Related Pain Produces Urinary Urge Incontinence. ( Hunsberger, J; Lee, W; Vickers, BA, 2017) |
| "Most recent cancer studies involving urethane-induced tumor formation use p53(+/-) mice, which lack one copy of the p53 tumor suppressor gene." | 1.43 | Effects of Repeated Anesthesia Containing Urethane on Tumor Formation and Health Scores in Male C57BL/6J Mice. ( Apple, T; Boyd, K; Bricker-Anthony, C; Rex, TS; Vail, K; Wallace, J, 2016) |
| "Pain is a significant side effect of disease, surgery and treatments including chemotherapy." | 1.43 | Pain management for chemotherapy-induced oral mucositis. ( Bennett, M, 2016) |
| "Intractable cancer-related pain complicated by a neuropathic component due to nerve impingement is poorly alleviated even by escalating doses of a strong opioid analgesic." | 1.42 | Novel polymeric bioerodable microparticles for prolonged-release intrathecal delivery of analgesic agents for relief of intractable cancer-related pain. ( Han, FY; Lam, AL; Smith, MT; Thurecht, KJ; Whittaker, AK, 2015) |
| "Ketamine is often used to manage neuropathic pain in patients with cancer." | 1.39 | Can gradual dose titration of ketamine for management of neuropathic pain prevent psychotomimetic effects in patients with advanced cancer? ( Matsuda, Y; Ohno, Y; Okamoto, Y; Tanimukai, H; Tsugane, M; Tsuneto, S; Uejima, E, 2013) |
| "The University of Washington Neuropathic Pain Scale was used to grade the neuropathic pain before and after use of the interventional gel." | 1.38 | Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: a pilot study. ( Gerbis, B; Gillis, D; Holwerda, E; Uzaraga, I; Wai, E, 2012) |
| "Pain was also improved, although for a shorter duration." | 1.38 | Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. ( Glue, P; Perez, D; Zanicotti, CG, 2012) |
| "In children with advanced stages of cancer, pain control remains inadequate in many patients and a solution to this problem is sorely lacking." | 1.34 | Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. ( Finkel, JC; Pestieau, SR; Quezado, ZM, 2007) |
| "Twelve patients with intractable cancer pain received a test dose of 5-10 mg of ketamine, a strong NMDA antagonist, in order to determine their response and tolerance to the drug." | 1.33 | Successful use of ketamine for intractable cancer pain. ( Body, JJ; Lossignol, DA; Obiols-Portis, M, 2005) |
| "Propofol was associated with faster onset, better recovery, early oral feeding time, no nausea and vomiting and better parental acceptability." | 1.31 | Propofol for pediatric radiotherapy. ( Bhatnagar, S; Kannan, TR; Mishra, S; Pandey, V; Panigrahi, M; Punj, J; Saxena, A, 2002) |
| "Two patients with far-advanced cancer, near death, who were experiencing excruciating and intractable pain that was poorly responsive to rapidly escalating doses of morphine and hydromorphone were treated with low-dose intravenous ketamine (0." | 1.30 | Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. ( Fine, PG, 1999) |
| "Ketamine is an NMDA-receptor antagonist that is used as an anesthetic and has been suggested as a useful drug for neuropathic pain." | 1.29 | Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. ( Calligara, M; Lodi, F; Mercadante, S; Sapio, M; Serretta, R, 1995) |
| "When ketamine was used as the sole anaesthetic agent, the induction of anaesthesia was frequently stressful and traumatic, with problems and difficulties being encountered during 24% of anaesthetics." | 1.27 | Anaesthesia and monitoring for paediatric radiotherapy. ( Casey, WF; Price, V; Smith, HS, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (7.38) | 18.7374 |
| 1990's | 12 (9.84) | 18.2507 |
| 2000's | 41 (33.61) | 29.6817 |
| 2010's | 45 (36.89) | 24.3611 |
| 2020's | 15 (12.30) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, TL | 1 |
| Mayence, A | 1 |
| Vanden Eynde, JJ | 1 |
| Forth, N | 1 |
| Nguyen, M | 1 |
| Grech, A | 1 |
| Singh, V | 1 |
| Gillespie, TW | 1 |
| Lane, O | 1 |
| Spektor, B | 1 |
| Zarrabi, AJ | 1 |
| Egan, K | 1 |
| Curseen, K | 1 |
| Tsvetkova, M | 1 |
| Beumer, JH | 1 |
| Sniecinski, R | 1 |
| Shteamer, JW | 1 |
| Switchenko, J | 1 |
| Harvey, RD | 1 |
| Mielke, N | 1 |
| Johnson, S | 1 |
| Bahl, A | 1 |
| Fadladdin, YAJ | 1 |
| Xue, M | 1 |
| Zhang, X | 7 |
| Chen, J | 3 |
| Liu, F | 1 |
| Xu, J | 3 |
| Xie, J | 1 |
| Yang, Y | 4 |
| Yu, W | 1 |
| Qiu, H | 1 |
| Xue, J | 2 |
| Jiang, J | 3 |
| Liu, Y | 10 |
| Shallom, SJ | 1 |
| Zelazny, AM | 1 |
| Giri, AR | 1 |
| Kaur, N | 1 |
| Yarrarapu, SNS | 1 |
| Rottman Pietrzak, KA | 1 |
| Santos, C | 1 |
| Lowman, PE | 1 |
| Niaz, S | 1 |
| Franco, PM | 1 |
| Sanghavi, DK | 1 |
| Zhu, D | 1 |
| Liang, R | 1 |
| Li, Z | 4 |
| Cheng, L | 1 |
| Ren, J | 1 |
| Guo, Y | 2 |
| Wang, M | 1 |
| Chai, H | 1 |
| Niu, Q | 1 |
| Yang, S | 2 |
| Bai, J | 2 |
| Yu, H | 2 |
| Zhang, H | 2 |
| Qin, X | 1 |
| Sahrakorpi, N | 1 |
| Engberg, E | 1 |
| Stach-Lempinen, B | 1 |
| Tammelin, TH | 1 |
| Kulmala, J | 1 |
| Roine, RP | 1 |
| Koivusalo, SB | 1 |
| Cheng, W | 1 |
| Pang, H | 1 |
| Campen, MJ | 1 |
| Zhang, J | 6 |
| Li, Y | 6 |
| Gao, J | 1 |
| Ren, D | 1 |
| Ji, X | 1 |
| Rothman, N | 1 |
| Lan, Q | 1 |
| Zheng, Y | 3 |
| Leng, S | 1 |
| Hu, Z | 2 |
| Tang, J | 4 |
| Dong, Q | 2 |
| Song, N | 1 |
| Qin, N | 1 |
| Chen, C | 1 |
| Sun, X | 2 |
| Easton, J | 1 |
| Mulder, H | 1 |
| Plyler, E | 1 |
| Neale, G | 1 |
| Walker, E | 1 |
| Li, Q | 1 |
| Ma, X | 2 |
| Chen, X | 4 |
| Huang, IC | 1 |
| Yasui, Y | 1 |
| Ness, KK | 1 |
| Hudson, MM | 1 |
| Robison, LL | 1 |
| Wang, Z | 3 |
| Subota, A | 1 |
| Spotswood, N | 1 |
| Roach, M | 1 |
| Goodarzi, Z | 1 |
| Holroyd-Leduc, J | 1 |
| Park, EA | 1 |
| Graves, SA | 1 |
| Menda, Y | 1 |
| Anghelescu, DL | 3 |
| Ryan, S | 1 |
| Wu, D | 1 |
| Morgan, KJ | 1 |
| Patni, T | 1 |
| Monsereenusorn, C | 2 |
| Malaithong, W | 1 |
| Lertvivatpong, N | 1 |
| Photia, A | 1 |
| Rujkijyanont, P | 2 |
| Traivaree, C | 2 |
| Chen, LK | 1 |
| Chen, SS | 1 |
| Shih, CH | 1 |
| Huang, ZX | 1 |
| Chen, L | 3 |
| Chen, KB | 1 |
| Cheung, KWA | 1 |
| Chan, PC | 1 |
| Lo, SH | 1 |
| Winegarden, JA | 1 |
| Carr, DB | 1 |
| Bradshaw, YS | 1 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 2 |
| Zhao, Y | 3 |
| Wang, J | 7 |
| Huang, L | 2 |
| Hu, K | 1 |
| Liu, H | 4 |
| Wang, H | 3 |
| Guo, Z | 1 |
| Song, Y | 1 |
| Huang, H | 4 |
| Yang, R | 1 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Wu, S | 1 |
| Cheng, T | 1 |
| Zhou, X | 1 |
| Wang, B | 4 |
| Zhang, Q | 4 |
| Wu, X | 2 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 3 |
| Gai, QY | 3 |
| Wang, W | 2 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Wang, X | 4 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Liu, J | 4 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 1 |
| Zhu, J | 2 |
| Jiang, H | 1 |
| He, C | 2 |
| Xiao, Z | 1 |
| Sun, Q | 1 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Zhu, L | 1 |
| Li, X | 4 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 5 |
| Liu, Z | 3 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 3 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Xu, N | 1 |
| Wang, R | 1 |
| Liu, S | 1 |
| He, H | 1 |
| Dong, X | 2 |
| Yang, M | 2 |
| Yang, Q | 1 |
| Duan, S | 1 |
| Yu, Y | 2 |
| Han, J | 2 |
| Zhang, C | 3 |
| Yang, X | 1 |
| Li, W | 3 |
| Wang, T | 2 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 4 |
| Yao, L | 2 |
| Sun, L | 3 |
| Zhu, Z | 1 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Lee, JH | 2 |
| Yoo, JS | 1 |
| Kim, Y | 1 |
| Kim, JS | 2 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Wang, C | 2 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Lu, Y | 1 |
| Yan, R | 1 |
| Zhang, Y | 6 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 1 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 1 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Wang, Y | 7 |
| Zhao, R | 1 |
| Gu, Z | 1 |
| Dong, C | 2 |
| Guo, G | 1 |
| Li, L | 4 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Zhu, X | 1 |
| Huang, X | 2 |
| Xu, H | 2 |
| Yang, G | 2 |
| Lin, Z | 1 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 2 |
| An, Z | 1 |
| Li, J | 7 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Wu, W | 1 |
| Song, J | 1 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Choi, J | 1 |
| Lim, YS | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Zhao, L | 1 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 1 |
| Yu, X | 2 |
| Wu, Y | 2 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 2 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 1 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 1 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Sun, J | 2 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 2 |
| Zheng, S | 2 |
| Ma, L | 1 |
| Wang, L | 3 |
| Hu, T | 1 |
| Wang, F | 1 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 1 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Xie, Y | 2 |
| Chen, Z | 2 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 1 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Zhang, Z | 2 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Guo, W | 1 |
| Liu, M | 2 |
| Liu, T | 2 |
| Chen, D | 5 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 1 |
| Sun, W | 1 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 1 |
| Kang, S | 1 |
| Duan, W | 1 |
| Zhang, S | 2 |
| Feng, J | 2 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 1 |
| Shang, Q | 1 |
| Zhao, W | 2 |
| Yang, Z | 2 |
| Jiang, X | 2 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 1 |
| Han, R | 1 |
| Cai, Y | 1 |
| Lv, YQ | 1 |
| Chen, Q | 1 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 1 |
| Xiao, X | 1 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Gao, F | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 1 |
| Yu, Q | 1 |
| Zhou, C | 1 |
| Liu, C | 2 |
| Liu, W | 1 |
| Chen, W | 1 |
| Yin, Y | 1 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 1 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Xu, Y | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Cao, Q | 1 |
| Yuan, X | 1 |
| Nie, W | 1 |
| Yang, J | 2 |
| Shao, B | 1 |
| Bi, Z | 1 |
| Liang, X | 1 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, Y | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 1 |
| Bi, W | 1 |
| Tang, H | 1 |
| Cui, Y | 1 |
| Zhang, L | 3 |
| Fan, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 2 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 1 |
| Li, C | 2 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 1 |
| Pang, B | 1 |
| Liu, Q | 2 |
| Liu, X | 3 |
| Huang, Y | 2 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 2 |
| Chua, H | 1 |
| Wang, K | 1 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Yu, J | 1 |
| Tian, J | 1 |
| Zhao, M | 1 |
| Hu, J | 1 |
| Yao, C | 1 |
| Zhang, B | 1 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 1 |
| Chi, T | 1 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 1 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 1 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 1 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 1 |
| Park, S | 1 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 1 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Lv, Y | 1 |
| Yuan, R | 1 |
| Cai, B | 1 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 3 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 1 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Choi, M | 1 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 1 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Shen, Y | 1 |
| Wang, Q | 2 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 1 |
| Liang, H | 1 |
| Xu, X | 1 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Wang, P | 1 |
| Mi, K | 1 |
| Cheng, J | 1 |
| Gu, C | 1 |
| Huang, J | 2 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Zhou, Y | 3 |
| Xue, H | 1 |
| Zhang, W | 1 |
| Ruan, Z | 1 |
| Li, S | 2 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 1 |
| Lin, S | 1 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 1 |
| Kong, X | 1 |
| Lu, J | 1 |
| Zhang, M | 1 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 1 |
| Luo, M | 1 |
| Wu, J | 1 |
| Cai, S | 1 |
| He, Y | 2 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Wu, P | 1 |
| Xu, L | 1 |
| Yuan, Y | 1 |
| Luo, J | 1 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Hu, Y | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 1 |
| Zhang, G | 1 |
| Jiang, F | 1 |
| Meng, X | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 1 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 1 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 1 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 1 |
| Liang, J | 1 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 1 |
| Lu, X | 1 |
| Wang, D | 1 |
| Hu, M | 1 |
| Shen, H | 1 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 1 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 1 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 1 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 1 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 1 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Prakash, S | 2 |
| Meena, JP | 2 |
| Gupta, AK | 2 |
| Bakhshi, S | 1 |
| Velpandian, T | 1 |
| Pandey, RM | 1 |
| Seth, R | 2 |
| Davis, MP | 1 |
| Chung, M | 1 |
| Benkli, B | 1 |
| Roldan, C | 1 |
| Qing, Y | 1 |
| Huh, B | 1 |
| Patel, S | 1 |
| Tatachar, V | 1 |
| Singh, AB | 1 |
| Galea, J | 1 |
| Fattakhov, E | 1 |
| Kaur, G | 1 |
| Oh, D | 1 |
| Haffey, P | 1 |
| Patel, A | 1 |
| Gulati, A | 1 |
| Yalçın Çok, O | 1 |
| Evren Eker, H | 1 |
| Arıboğan, A | 1 |
| Sexton, J | 1 |
| Atayee, RS | 1 |
| Bruner, HC | 1 |
| Tesney, JM | 1 |
| Courade, M | 1 |
| Bertrand, A | 1 |
| Guerrini-Rousseau, L | 1 |
| Pagnier, A | 1 |
| Levy, D | 1 |
| Lervat, C | 1 |
| Cojean, N | 1 |
| Ribrault, A | 1 |
| Dugue, S | 1 |
| Thouvenin, S | 1 |
| Piguet, C | 1 |
| Schmitt, C | 1 |
| Marec-Berard, P | 1 |
| Jackson, K | 4 |
| Franco, M | 2 |
| William, L | 2 |
| Poon, P | 2 |
| Pisasale, M | 3 |
| Kenner, D | 1 |
| Brumley, D | 3 |
| Mewett, G | 1 |
| Ashby, M | 3 |
| Viney, M | 1 |
| Kerr, D | 1 |
| Leppert, W | 1 |
| Hardy, J | 4 |
| Quinn, S | 3 |
| Fazekas, B | 4 |
| Eckermann, S | 2 |
| Agar, MR | 1 |
| Spruyt, O | 5 |
| Rowett, D | 3 |
| Currow, D | 3 |
| Mion, G | 1 |
| Marchetti, F | 1 |
| Samama, CM | 1 |
| Bredlau, AL | 1 |
| Thakur, R | 1 |
| Korones, DN | 1 |
| Dworkin, RH | 2 |
| Agar, M | 3 |
| Le, B | 1 |
| Philip, J | 2 |
| Gewandter, JS | 1 |
| Mohile, SG | 1 |
| Heckler, CE | 1 |
| Ryan, JL | 1 |
| Kirshner, JJ | 1 |
| Flynn, PJ | 1 |
| Hopkins, JO | 1 |
| Morrow, GR | 1 |
| Bell, RF | 5 |
| Jaksch, W | 1 |
| Kalso, EA | 2 |
| Le, BH | 1 |
| Hardy, JR | 1 |
| Quinn, SJ | 1 |
| Devilee, LR | 1 |
| Currow, DC | 2 |
| Hershman, DL | 1 |
| Lacchetti, C | 1 |
| Lavoie Smith, EM | 1 |
| Bleeker, J | 1 |
| Cavaletti, G | 1 |
| Chauhan, C | 1 |
| Gavin, P | 1 |
| Lavino, A | 1 |
| Lustberg, MB | 1 |
| Paice, J | 1 |
| Schneider, B | 1 |
| Smith, ML | 1 |
| Smith, T | 1 |
| Terstriep, S | 1 |
| Wagner-Johnston, N | 1 |
| Bak, K | 1 |
| Loprinzi, CL | 1 |
| Schreiber, JA | 1 |
| Mahling, M | 1 |
| Fuchs, K | 1 |
| Thaiss, WM | 1 |
| Maier, FC | 1 |
| Feger, M | 1 |
| Bukala, D | 1 |
| Harant, M | 1 |
| Eichner, M | 1 |
| Reutershan, J | 1 |
| Lang, F | 1 |
| Reischl, G | 1 |
| Pichler, BJ | 1 |
| Kneilling, M | 1 |
| Han, FY | 1 |
| Thurecht, KJ | 1 |
| Lam, AL | 1 |
| Whittaker, AK | 1 |
| Smith, MT | 1 |
| McCaffrey, N | 1 |
| Devilee, L | 1 |
| Quibell, R | 1 |
| Fallon, M | 1 |
| Mihalyo, M | 1 |
| Twycross, R | 1 |
| Wilcock, A | 1 |
| Rex, TS | 1 |
| Boyd, K | 1 |
| Apple, T | 1 |
| Bricker-Anthony, C | 1 |
| Vail, K | 1 |
| Wallace, J | 1 |
| Fan, W | 1 |
| Yang, H | 1 |
| Li, G | 1 |
| Bennett, M | 1 |
| Vickers, BA | 1 |
| Lee, W | 1 |
| Hunsberger, J | 1 |
| Sharma, SS | 1 |
| Sritharan, G | 1 |
| Mogos, M | 2 |
| Roffey, P | 3 |
| Thangathurai, D | 3 |
| Jost, L | 1 |
| Roila, F | 1 |
| Howell, D | 1 |
| Petersen, J | 1 |
| Good, P | 1 |
| Wein, S | 1 |
| Woodruff, R | 1 |
| Sato, C | 1 |
| Okabe, T | 1 |
| Nakanishi, K | 1 |
| Sakamoto, A | 1 |
| Benítez-Rosario, MA | 1 |
| Salinas-Martín, A | 1 |
| González-Guillermo, T | 1 |
| Feria, M | 1 |
| Chiaretti, A | 1 |
| Ruggiero, A | 1 |
| Barbi, E | 1 |
| Pierri, F | 1 |
| Maurizi, P | 1 |
| Fantacci, C | 1 |
| Bersani, G | 1 |
| Riccardi, R | 1 |
| Zhou, ZQ | 1 |
| Yang, JJ | 1 |
| Rakhman, E | 1 |
| Shmain, D | 1 |
| White, I | 1 |
| Ekstein, MP | 1 |
| Kollender, Y | 1 |
| Chazan, S | 1 |
| Dadia, S | 1 |
| Bickels, J | 1 |
| Amar, E | 1 |
| Weinbroum, AA | 1 |
| Rakes, LC | 1 |
| Shearer, JR | 1 |
| Bikhazi, GB | 1 |
| Uzaraga, I | 1 |
| Gerbis, B | 1 |
| Holwerda, E | 1 |
| Gillis, D | 1 |
| Wai, E | 1 |
| Salas, S | 1 |
| Frasca, M | 1 |
| Planchet-Barraud, B | 1 |
| Burucoa, B | 1 |
| Pascal, M | 1 |
| Lapiana, JM | 1 |
| Hermet, R | 1 |
| Castany, C | 1 |
| Ravallec, F | 1 |
| Loundou, A | 1 |
| Auquier, P | 1 |
| Duffaud, F | 1 |
| Baumstarck, K | 1 |
| Zanicotti, CG | 1 |
| Perez, D | 1 |
| Glue, P | 1 |
| Prommer, EE | 1 |
| Pirrello, RD | 1 |
| Okamoto, Y | 1 |
| Tsuneto, S | 1 |
| Tanimukai, H | 1 |
| Matsuda, Y | 1 |
| Ohno, Y | 1 |
| Tsugane, M | 1 |
| Uejima, E | 1 |
| Plummer, J | 1 |
| Eccleston, C | 3 |
| Punj, J | 1 |
| Bhatnagar, S | 3 |
| Saxena, A | 3 |
| Mishra, S | 2 |
| Kannan, TR | 2 |
| Panigrahi, M | 1 |
| Pandey, V | 1 |
| McQueen, AL | 1 |
| Baroletti, SA | 1 |
| Miles, J | 1 |
| Kong, PE | 1 |
| Snijdelaar, DG | 1 |
| Crul, BJ | 1 |
| Bell, R | 1 |
| Kalso, E | 3 |
| Mercadante, S | 6 |
| Villari, P | 3 |
| Ferrera, P | 3 |
| Prommer, E | 1 |
| Arcuri, E | 3 |
| Vranken, JH | 2 |
| van der Vegt, MH | 2 |
| Kal, JE | 1 |
| Kruis, MR | 2 |
| Wootton, M | 1 |
| Meyer, S | 2 |
| Aliani, S | 1 |
| Graf, N | 2 |
| Gottschling, S | 2 |
| Baudelet, C | 1 |
| Gallez, B | 1 |
| Ozdemir, D | 1 |
| Kayserili, E | 1 |
| Arslanoglu, S | 1 |
| Gulez, P | 1 |
| Vergin, C | 1 |
| Lossignol, DA | 1 |
| Obiols-Portis, M | 1 |
| Body, JJ | 1 |
| Fitzgibbon, EJ | 1 |
| Viola, R | 1 |
| Pasero, C | 1 |
| McCaffery, M | 1 |
| Troost, D | 1 |
| Wegener, JT | 1 |
| Krenn, T | 1 |
| Reinhard, H | 1 |
| Lothschuetz, D | 1 |
| Nunold, H | 1 |
| Mangione, S | 1 |
| Bentley, MW | 1 |
| Stas, JM | 1 |
| Johnson, JM | 1 |
| Viet, BC | 1 |
| Garrett, N | 1 |
| Pharo, GH | 1 |
| Kozek, SA | 1 |
| Sator-Katzenschlager, S | 1 |
| Kress, HG | 1 |
| Visser, E | 1 |
| Schug, SA | 1 |
| Wiffen, PJ | 1 |
| Ben-Ari, A | 1 |
| Lewis, MC | 1 |
| Davidson, E | 1 |
| Finkel, JC | 1 |
| Pestieau, SR | 1 |
| Quezado, ZM | 1 |
| Gupta, M | 1 |
| Srikanti, M | 1 |
| Mondol, A | 1 |
| Diwedi, A | 1 |
| Van Zundert, J | 1 |
| Van Boxem, K | 1 |
| Campbell-Fleming, JM | 1 |
| Williams, A | 1 |
| Lodi, F | 1 |
| Sapio, M | 1 |
| Calligara, M | 1 |
| Serretta, R | 1 |
| Muller, A | 1 |
| Lemos, D | 1 |
| De Conno, F | 1 |
| Polastri, D | 1 |
| Makin, MK | 1 |
| Ellershaw, JE | 1 |
| Fine, PG | 1 |
| Lauretti, GR | 2 |
| Lima, IC | 1 |
| Reis, MP | 2 |
| Prado, WA | 1 |
| Pereira, NL | 2 |
| Gomes, JM | 1 |
| Lawlor, PG | 1 |
| Tarumi, Y | 2 |
| Vielvoye-Kerkmeer, AP | 1 |
| van der Weide, M | 1 |
| Mattern, C | 1 |
| Pellier, I | 1 |
| Monrigal, JP | 1 |
| Le Moine, P | 1 |
| Rod, B | 1 |
| Rialland, X | 1 |
| Granry, JC | 1 |
| Shewale, S | 1 |
| Trikha, A | 1 |
| Singh, M | 1 |
| Sharief, A | 1 |
| Watanabe, S | 1 |
| Bruera, E | 1 |
| Ishitani, K | 1 |
| Tirelli, W | 1 |
| Casuccio, A | 1 |
| McDonnell, FJ | 1 |
| Sloan, JW | 1 |
| Hamann, SR | 1 |
| Martin, P | 1 |
| Hayes, B | 1 |
| Barry, A | 1 |
| Elavia, MH | 1 |
| Shah, SC | 1 |
| Savant, NS | 1 |
| Kanamaru, T | 1 |
| Saeki, S | 1 |
| Katsumata, N | 1 |
| Mizuno, K | 1 |
| Ogawa, S | 1 |
| Suzuki, H | 1 |
| Oshima, E | 1 |
| Tei, K | 1 |
| Kayazawa, H | 1 |
| Urabe, N | 1 |
| Iagubov, RS | 1 |
| Casey, WF | 1 |
| Price, V | 1 |
| Smith, HS | 1 |
| Harrison, CA | 1 |
| Filshie, J | 1 |
| Khonelidze, GB | 1 |
| Kamyshov, IaM | 1 |
| Piterskiĭ, NI | 1 |
| Soltan, AF | 1 |
| Gerasimova, GA | 1 |
| Feins, NR | 1 |
| Cronin, MM | 1 |
| Bousfield, JD | 1 |
| Hewett, EB | 1 |
| McLellan, I | 1 |
| Boulton, TB | 1 |
| Bertolini, G | 1 |
| Dauri, A | 1 |
| Roman, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Topical Treatment Response With Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy (ATTRACT-CPN)[NCT00471445] | Phase 3 | 462 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy[NCT04920097] | 240 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| Intravenous Lidocaine Infusion Versus Oral Duloxetine For The Prevention And Treatment Of Chemotherapy Induced Peripheral Neuropathy Among Breast Cancer Patients[NCT04732455] | 60 participants (Actual) | Interventional | 2021-01-15 | Completed | |||
| The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer[NCT04558034] | 14 participants (Actual) | Interventional | 2020-08-04 | Terminated (stopped due to Principal Investigator retired before study completed.) | |||
| Effect of Cryotherapy in Controlling Peripheral Neuropathy in Cancer Children[NCT04536207] | 60 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)[NCT04780854] | Phase 2 | 68 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)[NCT04299893] | Phase 2/Phase 3 | 42 participants (Anticipated) | Interventional | 2020-11-30 | Recruiting | ||
| Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study[NCT05798884] | 150 participants (Anticipated) | Interventional | 2023-05-31 | Not yet recruiting | |||
| EARLY PREOPERATIVE ESCALATING DOSES OF KETAMINE ATTENUATE POSTOPERATIVE PAIN AND REDUCE MORPHINE CONSUMPTION IN HUMANS[NCT01070108] | 120 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine[NCT03096444] | Phase 2 | 13 participants (Actual) | Interventional | 2017-05-23 | Terminated (stopped due to Efficacy was not seen after interim analysis) | ||
| A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients With Refractory Cancer Pain[NCT03362073] | Phase 2 | 26 participants (Anticipated) | Interventional | 2018-06-01 | Recruiting | ||
| Study of the Efficiency of the Ketamine With Low Analgesic Doses, in Association With High Opioids, in the Treatment of the Rebels Pains, in Palliative Phase of the Cancerous Disease[NCT01326325] | Phase 3 | 24 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Low-dose Ketamine as Adjuvant Treatment to Morphine in Neuropathic Cancer Pain[NCT01951911] | Phase 3 | 0 participants (Actual) | Interventional | 2013-09-30 | Withdrawn (stopped due to Poor patient recruitment. Vast majority of the patients have exclusions criteria) | ||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| A Randomized Controlled Trial to Determine the Efficacy of Ketamine as an Adjunct for Pain Management in Patients With Sickle Cell Crisis[NCT03502421] | Phase 3 | 0 participants (Actual) | Interventional | 2018-09-01 | Withdrawn (stopped due to Never IRB approved, no intention to proceed with the study) | ||
| Oral Ketamine for Control of Chronic Pain in Children[NCT01369680] | Phase 1 | 12 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| The Use of Ketamine as Rescue Analgesia in the Recovery Room Following Opioid Administration. A Double-blind Randomised Trial in Postoperative Patients.[NCT00163969] | Phase 4 | 40 participants | Interventional | 2002-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Cancer survivors who completed chemotherapy at least 1 month prior and had Chemotherapy Induced Peripheral Neuropathy (CIPN) (greater than or equal to 4 out of 10) were enrolled. CIPN was assessed using average scores from a 7-day daily diary that asks patients to rate the average pain, numbness, or tingling in their hands and feet over the past 24 hours on an 11-point numeric rating scale at baseline and 6 weeks post intervention. CIPN ranges from 0 (no pain) to 10 (worst possible pain)." (NCT00471445)
Timeframe: Week 6 - Baseline
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 6 | |
| Ketamine/Amitriptyline NP-H Cream | 6.55 | 4.93 |
| Placebo Cream | 6.47 | 5.19 |
"Peak itch intensity between the vehicle and 4 other active treatments (individual ketamine, amitriptyline, or lidocaine, and KeAmLi-combo). Itch intensity was measured on a 100mm scale visual analog scale for 10 minutes. 0 was weighted with no itch and 100 was weighted with most itch imaginable." (NCT03096444)
Timeframe: 10 minutes
| Intervention | Intensity score (Mean) |
|---|---|
| Topical KeAmLi Combo | 62.7 |
| Topical Ketamine | 63.1 |
| Topical Amitriptyline | 69.2 |
| Topical Lidocaine | 65.8 |
| Topical Vehicle | 61.9 |
Assess mechanical detection and pain thresholds using von Frey filaments stimulators (measured in force mN) to calculate the final threshold as the geometric mean of five series of ascending and descending stimuli. (NCT03096444)
Timeframe: 5 minutes
| Intervention | mN (Mean) | |
|---|---|---|
| Mechanical Detection Threshold | Mechanical Pain Threshold | |
| Topical Amitriptyline | 3.573423965 | 152.4768146 |
| Topical KeAmLi Combo | 3.519376956 | 152.3293608 |
| Topical Ketamine | 3.464204768 | 135.9 |
| Topical Lidocaine | 3.546037659 | 126.9 |
| Topical Vehicle | 3.525692637 | 148.7138273 |
Two standardized quantitative sensory tests are performed to measure warmth detection threshold (assesses the threshold of which warmth sensation is first detected) and heat pain threshold (assesses the threshold at which heat pain sensation is first detected). Measured in change in celsius. (NCT03096444)
Timeframe: 3 minutes
| Intervention | Degrees celsius (Mean) | |
|---|---|---|
| Warm Detection Threshold | Heat Pain Threshold | |
| Topical Amitriptyline | 33.9 | 40.0 |
| Topical KeAmLi Combo | 33.6 | 39.8 |
| Topical Ketamine | 34.0 | 40.0 |
| Topical Lidocaine | 33.7 | 39.4 |
| Topical Vehicle | 33.8 | 39.7 |
"Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.~The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores." (NCT01369680)
Timeframe: At 14 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 0 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 0 |
| Ketamine 1.5 mg/kg/Dose | 0 |
Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children. (NCT01369680)
Timeframe: At week 1
| Intervention | ng/mL (Mean) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 37.5 |
| Ketamine 0.5 mg/kg/Dose | 135 |
| Ketamine 1 mg/kg/Dose | 250 |
According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity. (NCT01369680)
Timeframe: Up to 2 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 3 |
| Ketamine 1 mg/kg/Dose | 3 |
| Ketamine 1.5 mg/kg/Dose | 1 |
"Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.~Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain." (NCT01369680)
Timeframe: Week 2
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 2 |
| Ketamine 1.5 mg/kg/Dose | 0 |
The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CY-BOCS Baseline | CY-BOCS Day 14 | |
| Ketamine Treatment Group | 29.00 | 26.20 |
The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CGI-S Baseline | CGI-S Day 14 | |
| Ketamine Treatment Group | 5.80 | 5.00 |
"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| OCD-VAS Baseline | OCD-VAS Day 14 | |
| Ketamine Treatment Group | 5.00 | 5.00 |
"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Y-BOCCS Baseline | Y-BOCCS Day 14 | |
| Ketamine Treatment Group | 18.25 | 16.50 |
26 reviews available for ketamine and Benign Neoplasms
| Article | Year |
|---|---|
Some non-conventional biomolecular targets for diamidines. A short survey.
Topics: Amidines; Animals; Diabetes Mellitus, Type 2; DNA; Enzymes; Humans; Hypertension; Ion Channels; Myot | 2014 |
Topics: Adult; Aging; Aluminum; Alzheimer Disease; Animals; Anti-Bacterial Agents; Artemisia annua; Body Mas | 2022 |
Topical Ketamine with Other Adjuvants: Underutilized for Refractory Cancer Pain? A Case Series and Suggested Revision of the World Health Organization Stepladder for Cancer Pain.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Humans; Ketamine; Neoplasms; Pain, Intractable; Retrosp | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
A review of the clinical applications of ketamine in pediatric oncology.
Topics: Analgesics; Child; Humans; Ketamine; Neoplasms; Pain; Prognosis | 2021 |
Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature.
Topics: Adult; Analgesics; Child; Clinical Trials as Topic; Humans; Ketamine; Neoplasms; Pain Management; Pa | 2013 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Understanding the cancer pain experience.
Topics: Acetaminophen; Analgesics; Chronic Pain; Critical Pathways; Fentanyl; Humans; Ketamine; Neoplasms; O | 2014 |
Ketamine.
Topics: Analgesics; Animals; Hospice Care; Humans; Ketamine; Neoplasms; Pain; Palliative Care | 2015 |
Ketamine for pain: an update of uses in palliative care.
Topics: Anesthetics, Dissociative; Humans; Ischemia; Ketamine; Neoplasms; Neuralgia; Pain; Palliative Care; | 2012 |
Ketamine as an adjuvant to opioids for cancer pain.
Topics: Adult; Analgesics; Chemotherapy, Adjuvant; Drug Therapy, Combination; Hallucinations; Humans; Ketami | 2012 |
Adjuvant ketamine analgesia for the management of cancer pain.
Topics: Adult; Analgesics; Germinoma; Humans; Injections, Intravenous; Ketamine; Male; Neoplasms; Pain; Test | 2002 |
Intrathecal therapy for chronic pain.
Topics: Administration, Oral; Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Chronic Disease; Hum | 2001 |
Ketamine as an adjuvant to opioids for cancer pain.
Topics: Adult; Analgesics; Chemotherapy, Adjuvant; Hallucinations; Humans; Ketamine; Morphine; Neoplasms; Pa | 2003 |
Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review.
Topics: Analgesics; Drug Therapy, Combination; Humans; Ketamine; Narcotics; Neoplasms; Pain; Palliative Care | 2003 |
Morphine is not the only analgesic in palliative care: literature review.
Topics: Analgesics; Analgesics, Opioid; Fentanyl; Humans; Ketamine; Methadone; Morphine; Neoplasms; Pain; Pa | 2004 |
Parenteral ketamine as an analgesic adjuvant for severe pain: development and retrospective audit of a protocol for a palliative care unit.
Topics: Adult; Aged; Analgesics; Dose-Response Relationship, Drug; Female; Humans; Infusions, Parenteral; Ke | 2005 |
Pain control: ketamine: low doses may provide relief for some painful conditions.
Topics: Analgesics; Chronic Disease; Drug Monitoring; Humans; Ketamine; Neoplasms; Pain | 2005 |
Pharmacologic management of cancer pain.
Topics: Adrenal Cortex Hormones; Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Anesthetics, Loca | 2005 |
The role of ketamine in pain management.
Topics: Analgesics; Chronic Disease; Humans; Ketamine; Neoplasms; Pain | 2006 |
The role of ketamine in pain management.
Topics: Analgesics; Chronic Disease; Humans; Ketamine; Neoplasms; Pain | 2006 |
The role of ketamine in pain management.
Topics: Analgesics; Chronic Disease; Humans; Ketamine; Neoplasms; Pain | 2006 |
The role of ketamine in pain management.
Topics: Analgesics; Chronic Disease; Humans; Ketamine; Neoplasms; Pain | 2006 |
Chronic administration of ketamine for analgesia.
Topics: Analgesics; Animals; Chronic Disease; Humans; Ketamine; Neoplasms; Pain, Intractable; Peripheral Ner | 2007 |
The use of ketamine as adjuvant therapy to control severe pain.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Drug Monitoring; Drug Therapy, | 2008 |
Ketamine in cancer pain: an update.
Topics: Analgesics, Opioid; Biological Availability; Drug Synergism; Drug Tolerance; Excitatory Amino Acid A | 1996 |
[Treatment of pain in oncology].
Topics: Administration, Cutaneous; Analgesics, Opioid; Anesthetics, Dissociative; Diphosphonates; Fentanyl; | 1997 |
Advances in cancer pain management.
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Bone Diseases; Bone Neoplasms; Chemothe | 2000 |
Pediatric surgery. Current concepts.
Topics: Abdomen; Ambulatory Care; Anesthesia, Inhalation; Anesthesia, Intravenous; Animals; Burns; Child; Ch | 1974 |
23 trials available for ketamine and Benign Neoplasms
| Article | Year |
|---|---|
The efficacy and safety of midazolam with fentanyl versus midazolam with ketamine for bedside invasive procedural sedation in pediatric oncology patients: A randomized, double-blinded, crossover trial.
Topics: Child; Cross-Over Studies; Fentanyl; Humans; Hypnotics and Sedatives; Ketamine; Midazolam; Neoplasms | 2022 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Ketamine mouthwash versus placebo in the treatment of severe oral mucositis pain in children with cancer: A randomized double-blind placebo-controlled trial.
Topics: Adolescent; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Cancer Pain; Child; Double-B | 2020 |
Ketamine dosing for sedation during repeated radiotherapy sessions in children
Topics: Anesthesia; Anesthetics, Dissociative; Child, Preschool; Drug Tolerance; Female; Humans; Hypnotics a | 2018 |
A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors.
Topics: Administration, Topical; Adult; Aged; Amitriptyline; Antineoplastic Agents; Double-Blind Method; Fem | 2014 |
The clinical effect of fentanyl in comparison with ketamine in analgesic effect for oncology procedures in children: a randomized, double-blinded, crossover trial.
Topics: Adolescent; Analgesics; Analgesics, Opioid; Child; Child, Preschool; Cross-Over Studies; Double-Blin | 2015 |
Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial.
Topics: Adult; Antidepressive Agents; Depression; Female; Humans; Ketamine; Male; Midazolam; Middle Aged; Ne | 2017 |
The effectiveness and adverse effects profile of "burst" ketamine in refractory cancer pain: The VCOG PM 1-00 study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Clinical Protocols; Drug Administration Schedule; Female | 2010 |
A strategy for conversion from subcutaneous to oral ketamine in cancer pain patients: effect of a 1:1 ratio.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Dose-Response Relationship, Drug; | 2011 |
Comparison of propofol versus propofol-ketamine combination in pediatric oncologic procedures performed by non-anesthesiologists.
Topics: Biopsy, Needle; Bone Marrow Examination; Child; Conscious Sedation; Female; Humans; Hypnotics and Se | 2011 |
Repeated and escalating preoperative subanesthetic doses of ketamine for postoperative pain control in patients undergoing tumor resection: a randomized, placebo-controlled, double-blind trial.
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Dose-Respons | 2011 |
Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care.
Topics: Adult; Aged; Analgesics; Biomedical Research; Double-Blind Method; Female; Humans; Infusions, Intrav | 2012 |
Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain.
Topics: Age Factors; Aged; Aged, 80 and over; Analgesics; Dose-Response Relationship, Drug; Double-Blind Met | 2012 |
Inter- and intraindividual variability in ketamine dosage in repetitive invasive procedures in children with malignancies.
Topics: Adolescent; Anesthetics, Dissociative; Biopsy; Bone Marrow Examination; Child; Child, Preschool; Dia | 2004 |
Ketamine and midazolam for invasive procedures in children with malignancy: a comparison of routes of intravenous, oral, and rectal administration.
Topics: Administration, Oral; Administration, Rectal; Anesthesia Recovery Period; Anesthetics, Combined; Ane | 2004 |
Propofol versus midazolam/ketamine for procedural sedation in pediatric oncology.
Topics: Adolescent; Anesthetics, Dissociative; Child; Child, Preschool; Conscious Sedation; Humans; Hypnotic | 2005 |
Effects of preincisional ketamine treatment on natural killer cell activity and postoperative pain management after oral maxillofacial surgery.
Topics: Adolescent; Adult; Aged; Analgesics; Female; Humans; Ketamine; Killer Cells, Natural; Male; Middle A | 2005 |
Efficacy and safety of a mixture of ketamine, midazolam and atropine for procedural sedation in paediatric oncology: a randomised study of oral versus intramuscular route.
Topics: Administration, Oral; Anesthetics, Combined; Atropine; Child; Child, Preschool; Humans; Hypnotics an | 2008 |
Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Humans; Ke | 1999 |
Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Humans; Ke | 1999 |
Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Humans; Ke | 1999 |
Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Humans; Ke | 1999 |
Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy.
Topics: Adult; Aged; Analgesia, Epidural; Double-Blind Method; Drug Synergism; Female; Humans; Ketamine; Mal | 1999 |
Oral ketamine for radiotherapy in children with cancer.
Topics: Administration, Oral; Anesthetics, Dissociative; Child, Preschool; Conscious Sedation; Female; Human | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients.
Topics: Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Drug Therapy, Combination; Female; Huma | 2002 |
Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients.
Topics: Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Drug Therapy, Combination; Female; Huma | 2002 |
Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients.
Topics: Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Drug Therapy, Combination; Female; Huma | 2002 |
Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients.
Topics: Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Drug Therapy, Combination; Female; Huma | 2002 |
74 other studies available for ketamine and Benign Neoplasms
| Article | Year |
|---|---|
A Case Report of Subanesthetic Ketamine Bolus and Infusion for Opioid Refractory Cancer Pain.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Humans; Ketamine; Neoplasms; Pain, Intractable | 2022 |
A dose-escalation clinical trial of intranasal ketamine for uncontrolled cancer-related pain.
Topics: Adult; Analgesics; Analgesics, Opioid; Cancer Pain; Double-Blind Method; Humans; Ketamine; Neoplasms | 2022 |
Low-dose ketamine infusions reduce opioid use in pediatric and young adult oncology patients.
Topics: Acute Pain; Analgesics; Analgesics, Opioid; Child; Death; Humans; Infusions, Intravenous; Ketamine; | 2022 |
Ketamine Promoted Breast Cancer Invasion and Metastasis Through Up-regulating Wnt, BMP, and EGFR Signaling.
Topics: Animals; Cell Line, Tumor; ErbB Receptors; Gene Expression Regulation, Neoplastic; Ketamine; Mice; N | 2023 |
The use of ketamine in the management of refractory cancer pain in a palliative care unit.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Humans; Ketamine; Neoplasms; Palliative Care; Retrospec | 2020 |
Topical Ketamine and Revision of the World Health Organization Step Ladder for Cancer Pain.
Topics: Analgesics; Cancer Pain; Humans; Ketamine; Neoplasms; Pain; World Health Organization | 2020 |
Subanesthetic ketamine in the ambulatory setting for refractory cancer pain: a 6-year retrospective at a cancer center.
Topics: Analgesics; Cancer Pain; Humans; Ketamine; Neoplasms; Pain, Intractable; Quality of Life; Retrospect | 2021 |
Low-dose ketamine as an adjuvant for pain control in a cancer patient: a case report.
Topics: Analgesics; Analgesics, Opioid; Emergency Service, Hospital; Humans; Ketamine; Male; Neoplasms; Pain | 2021 |
Intravenous Ketamine for Cancer Pain Management, Including Flares During the COVID-19 Pandemic: A Retrospective Study.
Topics: Analgesics; COVID-19; Humans; Infusions, Intravenous; Ketamine; Neoplasms; Pain Management; Pandemic | 2021 |
Case Report: Ketamine for Pain and Depression in Advanced Cancer.
Topics: Analgesics; Depression; Humans; Ketamine; Male; Middle Aged; Neoplasms; Pain; Treatment Outcome | 2018 |
Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm.
Topics: Adult; Algorithms; Analgesics; Child; Chronic Pain; Clinical Decision-Making; Humans; Ketamine; Medi | 2019 |
Low-dose ketamine adjuvant treatment for refractory pain in children, adolescents and young adults with cancer: a pilot study.
Topics: Adolescent; Analgesics; Analgesics, Opioid; Cancer Pain; Child; Child, Preschool; Humans; Ketamine; | 2022 |
Ketamine and cancer pain: the reports of my death have been greatly exaggerated.
Topics: Female; Humans; Ketamine; Male; Neoplasms; Pain, Intractable | 2013 |
Ketamine in the management of cancer pain.
Topics: Female; Humans; Ketamine; Male; Neoplasms; Pain, Intractable | 2013 |
Reply to K. Jackson et al and W. Leppert.
Topics: Female; Humans; Ketamine; Male; Neoplasms; Pain, Intractable | 2013 |
[Compassionate use of intrathecal ketamine for intractable cancer pain].
Topics: Anesthetics, Dissociative; Humans; Injections, Spinal; Ketamine; Neoplasms; Neuralgia; Pain, Intract | 2013 |
Can the LANSS scale be used to classify pain in chronic cancer pain trials?
Topics: Aged; Analgesics; Female; Humans; Ketamine; Male; Middle Aged; Neoplasms; Neuralgia; Nociceptive Pai | 2013 |
Integrating new evidence about an old drug: growing pains as palliative medicine matures.
Topics: Female; Humans; Ketamine; Male; Neoplasms; Pain, Intractable | 2013 |
Critical appraisal of randomized controlled trials: the beginning of thought….
Topics: Female; Humans; Ketamine; Male; Neoplasms; Pain, Intractable | 2014 |
Interpreting the evidence: reply to Spruyt et al.
Topics: Female; Humans; Ketamine; Male; Neoplasms; Pain, Intractable | 2014 |
Integrating new evidence about an old drug: authors' reply to Franco et al. and Bell et al.
Topics: Female; Humans; Ketamine; Male; Neoplasms; Pain, Intractable | 2014 |
Implementing practice change in chronic cancer pain management: clinician response to a phase III study of ketamine.
Topics: Adult; Aged; Attitude of Health Personnel; Chronic Pain; Clinical Trials, Phase III as Topic; Diffus | 2014 |
A Comparative pO2 Probe and [18F]-Fluoro-Azomycinarabino-Furanoside ([18F]FAZA) PET Study Reveals Anesthesia-Induced Impairment of Oxygenation and Perfusion in Tumor and Muscle.
Topics: Anesthesia; Animals; Blood Pressure; Cell Line, Tumor; Female; Isoflurane; Ketamine; Mice, Inbred BA | 2015 |
Novel polymeric bioerodable microparticles for prolonged-release intrathecal delivery of analgesic agents for relief of intractable cancer-related pain.
Topics: Analgesics; Analgesics, Opioid; Animals; Delayed-Action Preparations; Ketamine; Lactic Acid; Male; M | 2015 |
Potential economic impact on hospitalisations of the Palliative Care Clinical Studies Collaborative (PaCCSC) ketamine randomised controlled trial.
Topics: Analgesics; Chronic Disease; Cost Savings; Hospitalization; Humans; Ketamine; Neoplasms; Pain Manage | 2016 |
Effects of Repeated Anesthesia Containing Urethane on Tumor Formation and Health Scores in Male C57BL/6J Mice.
Topics: Anesthetics; Animals; Carcinogens; Ketamine; Male; Mice; Mice, Inbred C57BL; Neoplasms; Urethane; Xy | 2016 |
Pain management for chemotherapy-induced oral mucositis.
Topics: Administration, Intravenous; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Cancer Pain; Chi | 2016 |
A Case Report: Subanesthetic Ketamine Infusion for Treatment of Cancer-Related Pain Produces Urinary Urge Incontinence.
Topics: Analgesics; Female; Humans; Infusions, Intravenous; Ketamine; Neoplasms; Pain; Pain Measurement; Uri | 2017 |
Fentanyl and ketamine used for postoperative pain control in high-risk patients with malignancy.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Fentanyl; Humans; Ketamine; Neoplasms; Pain, Postoper | 2009 |
Management of cancer pain: ESMO Clinical Practice Guidelines.
Topics: Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; D | 2010 |
Posttraumatic stress disorder in cancer ICUs.
Topics: Anesthetics, Dissociative; Drug Therapy, Combination; Fentanyl; Humans; Intensive Care Units; Ketami | 2010 |
A case of cancer pain management by long-term intrathecal PCA.
Topics: Adult; Analgesia, Patient-Controlled; Bupivacaine; Female; Humans; Injections, Spinal; Ketamine; Mor | 2010 |
Be prudent of ketamine in treating resistant depression in patients with cancer.
Topics: Analgesics; Depression; Humans; Ketamine; Neoplasms; Patients | 2011 |
Prevention of emergence agitation in seven children receiving low-dose ketamine and propofol total intravenous anesthesia.
Topics: Anesthetics, Dissociative; Anesthetics, Intravenous; Child, Preschool; Drug Interactions; Humans; In | 2011 |
Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: a pilot study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Amitriptyline; Analgesics; Anesthetics, L | 2012 |
Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer.
Topics: Adult; Anesthetics, Dissociative; Depressive Disorder, Major; Disease Progression; Dysthymic Disorde | 2012 |
Response to ketamine article.
Topics: Analgesics; Biomedical Research; Female; Humans; Infusions, Intravenous; Ketamine; Male; Neoplasms; | 2012 |
Can gradual dose titration of ketamine for management of neuropathic pain prevent psychotomimetic effects in patients with advanced cancer?
Topics: Adolescent; Adult; Aged; Analgesics; Child; Female; Humans; Infusions, Intravenous; Ketamine; Male; | 2013 |
Propofol for pediatric radiotherapy.
Topics: Anesthetics, Dissociative; Anesthetics, Intravenous; Child; Child, Preschool; Female; Humans; Infant | 2002 |
[Parenteral administration of low dose ketamine for the treatment of neuropathic pain in cancer patients].
Topics: Adult; Analgesics; Female; Humans; Infusions, Parenteral; Ketamine; Male; Middle Aged; Neoplasms; Ne | 2002 |
Burst ketamine to reverse opioid tolerance in cancer pain.
Topics: Aged; Analgesics, Opioid; Drug Tolerance; Excitatory Amino Acid Antagonists; Female; Humans; Ketamin | 2003 |
Ketamine to control pain.
Topics: Adult; Analgesics; Fatal Outcome; Female; Humans; Infusions, Intravenous; Ketamine; Neoplasms; Pain | 2003 |
Local anesthetic switching for intrathecal tachyphylaxis in cancer patients with pain.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Anesthetics, Local; Bupivacaine; Humans; Injections, | 2004 |
Treatment of neuropathic cancer pain with continuous intrathecal administration of S +-ketamine.
Topics: Aged; Analgesics; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Neoplasms; Pain, Intr | 2004 |
Effect of anesthesia on the signal intensity in tumors using BOLD-MRI: comparison with flow measurements by Laser Doppler flowmetry and oxygen measurements by luminescence-based probes.
Topics: Anesthetics; Animals; Droperidol; Fentanyl; Isoflurane; Ketamine; Laser-Doppler Flowmetry; Magnetic | 2004 |
Successful use of ketamine for intractable cancer pain.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combinati | 2005 |
Neuropathological findings after continuous intrathecal administration of S(+)-ketamine for the management of neuropathic cancer pain.
Topics: Analgesics; Female; Humans; Ketamine; Middle Aged; Neoplasms; Pain; Postmortem Changes; Spinal Cord | 2005 |
Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain.
Topics: Administration, Sublingual; Adult; Aged; Analgesics; Anesthetics, Local; Bupivacaine; Female; Humans | 2005 |
Intrathecal S(+)-ketamine in refractory neuropathic cancer pain.
Topics: Anesthetics, Dissociative; Brain Stem; Gliosis; Humans; Injections, Spinal; Ketamine; Male; Neoplasm | 2006 |
Subanesthetic ketamine for cancer pain and scientific rigor in cancer pain trials. A reply to Jackson et al.
Topics: Analgesics; Clinical Trials as Topic; Humans; Ketamine; Neoplasms; Pain | 2006 |
Evidence-based pain management and palliative care in Issue One for 2006 of The Cochrane Library.
Topics: Analgesics; Analgesics, Opioid; Clinical Trials as Topic; Cryotherapy; Evidence-Based Medicine; Huma | 2006 |
Low incidence of dry mouth in patients with cancer with the use of ketamine.
Topics: Analgesics; Humans; Incidence; Ketamine; Neoplasms; Palliative Care; Risk Factors; Xerostomia | 2007 |
Ketamine as an adjuvant for treatment of cancer pain in children and adolescents.
Topics: Adolescent; Age Factors; Analgesics, Opioid; Child; Child, Preschool; Dose-Response Relationship, Dr | 2007 |
World Institute of Pain (WIP)--Fourth World Congress.
Topics: Animals; Back Pain; Clinical Trials as Topic; Humans; Ketamine; Neoplasms; Pain; Pain Management; Ra | 2007 |
Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain.
Topics: Aged; Excitatory Amino Acid Antagonists; Humans; Infusions, Parenteral; Ketamine; Male; Neoplasms; N | 1995 |
[Cancer pain: beneficial effect of ketamine addition to spinal administration of morphine-clonidine-lidocaine mixture].
Topics: Aged; Analgesics; Catheters, Indwelling; Clonidine; Drug Combinations; Drug Synergism; Female; Human | 1996 |
Substitution of another opioid for morphine. Methadone can be used to manage neuropathic pain related to cancer.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Humans; Ketamine; Methadone; N-Methylaspartate; Neopl | 1998 |
Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain.
Topics: Adolescent; Adult; Analgesics; Female; Humans; Ketamine; Neoplasms; Pain, Intractable; Terminal Care | 1999 |
Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain.
Topics: Adolescent; Adult; Analgesics; Female; Humans; Ketamine; Neoplasms; Pain, Intractable; Terminal Care | 1999 |
Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain.
Topics: Adolescent; Adult; Analgesics; Female; Humans; Ketamine; Neoplasms; Pain, Intractable; Terminal Care | 1999 |
Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain.
Topics: Adolescent; Adult; Analgesics; Female; Humans; Ketamine; Neoplasms; Pain, Intractable; Terminal Care | 1999 |
Low-dose subcutaneous ketamine infusion and morphine tolerance.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Drug Administration Schedule; Female; Humans; Ketamine; | 1999 |
Low-dose subcutaneous ketamine infusion and morphine tolerance.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Drug Administration Schedule; Female; Humans; Ketamine; | 1999 |
Low-dose subcutaneous ketamine infusion and morphine tolerance.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Drug Administration Schedule; Female; Humans; Ketamine; | 1999 |
Low-dose subcutaneous ketamine infusion and morphine tolerance.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Drug Administration Schedule; Female; Humans; Ketamine; | 1999 |
The need for ketamine.
Topics: Analgesics; Humans; Ketamine; Neoplasms; Palliative Care | 2000 |
Re: Clinical experience with oral ketamine.
Topics: Administration, Oral; Humans; Ketamine; Neoplasms; Palliative Care | 2000 |
Use of intravenous ketamine-midazolam association for pain procedures in children with cancer. A prospective study.
Topics: Adolescent; Analgesics; Biopsy; Biopsy, Needle; Blood Pressure; Catheterization, Central Venous; Chi | 1999 |
High-dose ketamine in the management of cancer-related neuropathic pain.
Topics: Analgesics; Dose-Response Relationship, Drug; Female; Humans; Ketamine; Middle Aged; Neoplasms; Neur | 2000 |
"Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients.
Topics: Adult; Aged; Analgesics; Female; Humans; Infusions, Intravenous; Ketamine; Male; Medical Audit; Midd | 2001 |
"Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients.
Topics: Adult; Aged; Analgesics; Female; Humans; Infusions, Intravenous; Ketamine; Male; Medical Audit; Midd | 2001 |
"Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients.
Topics: Adult; Aged; Analgesics; Female; Humans; Infusions, Intravenous; Ketamine; Male; Medical Audit; Midd | 2001 |
"Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients.
Topics: Adult; Aged; Analgesics; Female; Humans; Infusions, Intravenous; Ketamine; Male; Medical Audit; Midd | 2001 |
Ketamine HC1 as sole anaesthetic agent for children undergoing radiotherapy.
Topics: Child; Child, Preschool; Humans; Immobilization; Infant; Ketamine; Neoplasms | 1978 |
[Ketamine infusion for control of pain in patients with advanced cancer].
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Infusions, Intravenous; Ketamine; Male; Middle Aged; | 1990 |
Continuous subcutaneous injection of ketamine for cancer pain.
Topics: Humans; Ketamine; Neoplasms; Pain, Intractable | 1990 |
[Effect of ketalar on the hypophyseo-adrenal system and glucose-insular homeostasis in children with malignant neoplasms].
Topics: Adrenocorticotropic Hormone; Anesthesia, Intravenous; Blood Glucose; Child; Child, Preschool; Growth | 1987 |
Anaesthesia and monitoring for paediatric radiotherapy.
Topics: Anesthesia, General; Anesthesia, Inhalation; Child, Preschool; Cyclopropanes; Enflurane; Female; Hum | 1986 |
The use of Hickman-Broviac catheters for paediatric radiotherapy.
Topics: Anesthesia, Intravenous; Brain Neoplasms; Catheters, Indwelling; Child, Preschool; Female; Humans; I | 1986 |
[Combination electroanesthesia in oncological patients during surgery and in the early postoperative period].
Topics: Aged; Anesthesia, Intravenous; Diazepam; Electronarcosis; Humans; Hydroxybutyrates; Ketamine; Middle | 1985 |
Ketamine anaesthesia for radiotherapy in small children.
Topics: Anesthesia, General; Anesthetics; Atropine; Blood Platelets; Body Weight; Child, Preschool; Cyclohex | 1972 |
[Preliminary observations on the use of ketamine in plastic and reconstructive surgery].
Topics: Abdomen; Adolescent; Adult; Anesthesia; Cardiovascular System; Child; Child, Preschool; Extremities; | 1973 |
[A new non-barbiturate anesthetic: 2(0-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride (Ketalar)].
Topics: Anesthesia; Animals; Cyclohexanes; Humans; Ketamine; Neoplasms | 1972 |